2089-80-7

Usage

Uses

Used in Pharmaceutical Industry:
1-Naphthalenecarboxaldehyde, 2,3-dihydroxyis used as a pharmaceutical agent for its potential antioxidant properties. Its ability to neutralize free radicals and protect cells from oxidative damage makes it a valuable compound in the development of treatments for various diseases and conditions associated with oxidative stress.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 1-Naphthalenecarboxaldehyde, 2,3-dihydroxyis used as an antimicrobial agent. Its potential to inhibit the growth of harmful microorganisms, such as bacteria and fungi, makes it a promising candidate for the development of new antimicrobial drugs and treatments.
Used in Flavor and Fragrance Industry:
1-Naphthalenecarboxaldehyde, 2,3-dihydroxyis used as a flavoring agent and fragrance ingredient in the food and cosmetics industries. Its unique aroma and taste profile, derived from its natural occurrence in cloves and tea plant flowers, make it a valuable component in the creation of various flavor and fragrance formulations.
Used in Chemical Synthesis:
In the field of organic chemistry, 1-Naphthalenecarboxaldehyde, 2,3-dihydroxyserves as a key intermediate in the synthesis of various complex organic compounds. Its unique structure and reactivity make it a versatile building block for the development of new pharmaceuticals, agrochemicals, and other specialty chemicals.

Upstream product

• 92-44-4 2,3-naphthalenediol 
• 557-21-1 dicyanozinc 
• 68-12-2 N,N-dimethyl-formamide 
• 3473-63-0 formamidine acetic acid 
• 20259-00-1 1-(phenylimino-methyl)-naphthalene-2,3-diol 

Downstream Products

• 56252-09-6 2,3-Dimethoxy-naphthalene-1-carbaldehyde 
• 56252-11-0 β-(2.3-Dimethoxy-1-naphthyl)-propionsaeure 
• 56252-10-9 (E)-β-(2.3-Dimethoxy-1-naphthyl)acrylsaeure 
• 182684-18-0 2-ethoxycarbonyl-5-hydroxy-3-oxo-3H-naphtho<2,1-b>pyrane 
• 667456-64-6 5-hydroxy-3H-benzo[f]chromen-3-one 

Relevant academic research and scientific papers

Synthesis and cytotoxicity of 5-deazaflavins containing o- and p-quinone moieties

A series of 5-deazaflavo-10,11-quinones having o-quinone structure in the molecule were synthesized. The cytotoxicity of 5-deazaflavo-6,9-quinones (p-quinone derivatives) and 5-deazaflavo-10,11-quinones (o-quinones) was evaluated in vitro against L1210 and KB cells. Some of the synthesized compounds exhibited cytotoxic activity comparable to that of mytomycin C.

Construction of Highly Functionalized Xanthones via Rh-Catalyzed Cascade C-H Activation/ O-Annulation

A facile and efficient strategy for obtaining functionalized and multihydroxylated xanthones via Rh catalysis under redox-neutral conditions is developed. Diverse salicylaldehydes bearing heterocycles, aromatics, and fused aromatics can be rapidly coupled with 1,4-benzoquinones or 1,4-hydroquinones to afford valuable xanthones via cascade C-H/O-H functionalization and annulation. This protocol provides a rapid synthetic approach to obtain biologically active materials through late-stage functionalization and prepares natural products such as subelliptenone, pruniflorone N, and ravenelin.

Derivatives of naphthalene with comt inhibiting activity

Compounds of formula (I′), wherein A, R1 to R3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.

N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists

Compounds of formula (I), wherein R2is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.

Imidazole derivatives

Tricyclic imidazole derivatives of the formula STR1 wherein R1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R2 is hydrogen or lower alkyl, R3 and R4, independently, are hydrogen or lower alkyl, A is a group of the formula STR2 m is the integer 2 or 3, R5, R6, R7 and R8, independently, are hydrogen or lower alkyl, and R9 is hydrogen and R10 is hydrogen or lower alkyl or R9 and R10 taken together are oxo, provided that at least one of R3 and R4 is lower alkyl when A is a group of the formula and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.